Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation

Annals of Oncology

Volumn 25, Issue 2, 2014, Pages 404-408

  Pietrantonio, F ^a   Perrone, F ^a   De Braud, F ^a   Castano, A ^a   Maggi, C ^a   Bossi, I ^a   Gevorgyan, A ^a   Biondani, P ^a   Pacifici, M ^a   Busico, A ^a   Gariboldi, M ^a,b   Festinese, F ^a   Tamborini, E ^a   Di Bartolomeo, M ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

Clinical trial; Colorectal cancer; MGMT; Temozolomide

Indexed keywords

B RAF KINASE; K RAS PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P53; TEMOZOLOMIDE; TUMOR MARKER; ALKYLATING AGENT; DACARBAZINE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR SUPPRESSOR PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; BRAF GENE; CANCER CHEMOTHERAPY; CHOLANGITIS; CLINICAL ARTICLE; COLORECTAL CANCER; DNA METHYLATION; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; KRAS GENE; MALE; METASTASIS; MGMT GENE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NRAS GENE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; WILD TYPE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; DRUG RESISTANCE; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; COLORECTAL NEOPLASMS; DACARBAZINE; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 84893347899     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt547     Document Type: Article

References (25)

1. Heinemann V, Douillard JY, Ducreux M et al. Targeted therapy in metastatic colorectal cancer-an example of personalised medicine in action. Cancer Treat Rev 2013; 39: 592-601.
2. Grothey A, Van Cutsem E, Sobrero A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 303-312.
3. Shen L, Kondo Y, Rosner GL et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005; 97: 1330-1338.
4. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 2000; 60: 2368-2371.
5. Pegg AE. Repair of O(6)-alkylguanine by alkyltransferases. Mutat Res 2000; 462: 83-100.
6. Kaina B, Ochs K, Grosch S et al. BER, MGMT, and MMR in defense against alkylation-induced genotoxicity and apoptosis. Prog Nucleic Acid Res Mol Biol 2001; 68: 41-54.
7. 6-methylguanine-DNA methyltransferase promoter: correlation with gene suppression. Carcinogenesis 1995; 16: 1385-1390.
8. 6-methylguanine DNA methyltransferase in human cancer. Oncogene 2004; 23: 1-8.
9. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
10. Von Hoff DD, Stephenson JJ, Jr, Rosen P et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010; 28: 4877-4883.
11. Shacham-Shmueli E, Beny A, Geva R et al. Response to temozolomide in patients with metastatic colorectal cancer with loss of MGMT expression: a new approach in the era of personalized medicine? J Clin Oncol 2011; 29: e262-e265.
12. Herman JG, Graff JR, Myohanen S et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821-9826.
13. Perrone F, Lampis A, Orsenigo M et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 2009; 20: 84-90.
14. Perrone F, Da Riva L, Orsenigo M et al. PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor. Neuro Oncol 2009; 11: 725-736.
15. Suraweera N, Duval A, Reperant M et al. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 2002; 123: 1804-1811.
16. Kato S, Han SY, Liu W et al. Understanding the function-structure and function- mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 2003; 100: 8424-8429.
17. Ku GY, Krol G, Ilson DH. Successful treatment of leptomeningeal disease in colorectal cancer with a regimen of bevacizumab, temozolomide, and irinotecan. J Clin Oncol 2007; 25: 14-16.
18. Khan OA, Ranson M, Michael M et al. A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. Br J Cancer 2008; 98: 1614-1618.
19. Amatu A, Sartore-Bianchi A, Moutinho C et al. Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer. Clin Cancer Res 2013; 19: 2265-2272.
20. 6-methylguanine-DNA methyltransferase promoter. Mol Cancer Ther 2013; 12: 809-818.
21. Whitehall VL, Walsh MD, Young J et al. Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability. Cancer Res 2001; 61: 827-830.
22. Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247-257.
23. Yip S, Miao J, Cahill DP et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res 2009; 15: 4622-4629.
24. Stefanius K, Ylitalo L, Tuomisto A et al. Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma. Histopathology 2011; 58: 679-692.
25. Sato A, Sunayama J, Matsuda K et al. MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis. Stem Cells 2011; 29: 1942-1951.